Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression

Cytokine

Volumn 61, Issue 3, 2013, Pages 970-977

  Gui, Dingkun ^a   Huang, Jianhua ^b   Guo, Yongping ^a   Chen, Jianguo ^c   Chen, Yifang ^c   Xiao, Wenzhen ^a   Liu, Xusheng ^d   Wang, Niansong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b FUDAN UNIVERSITY   (China)

^c ZHEJIANG HOSPITAL   (China)

^d GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

Author keywords

Astragaloside IV; Diabetic nephropathy; Inflammation; NF B

Indexed keywords

ASTRAGALOSIDE IV; CHOLESTEROL; COLLAGEN TYPE 4; CREATININE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITROGEN; TUMOR NECROSIS FACTOR ALPHA; UREA;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOSE RESPONSE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INFLAMMATION; KIDNEY CORTEX; KIDNEY INJURY; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING;

ALBUMINURIA; ANIMALS; BIOLOGICAL MARKERS; CHEMOKINE CCL2; COLLAGEN TYPE IV; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION REGULATION; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY DISEASES; MALE; NF-KAPPA B; PODOCYTES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SAPONINS; TRITERPENES; TUMOR NECROSIS FACTOR-ALPHA;

ASTRAGALUS MEMBRANACEUS; RATTUS;

EID: 84875378096     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.01.008     Document Type: Article

References (42)

1. Svensson M., Sundkvist G., Arnqvist H.J., Björk E., Blohmé G., Bolinder J., et al. Signs of nephropathy may occur early in young adults with diabetes despite modern diabetes management: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 2003, 26:2903-2909.
2. Tuttle K.R. Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol 2005, 16:1537-1538.
3. Mora C., Navarro J.F. Inflammation and diabetic nephropathy. Curr Diab Rep 2006, 6:463-468.
4. Navarro-Gonzalez J.F., Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008, 19:433-442.
5. Sassy-Prigent C., Heudes D., Mandet C., Bélair M.F., Michel O., Perdereau B., et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 2000, 49:466-475.
6. Chow F., Ozols E., Nikolic-Paterson D.J., Atkins R.C., Tesch G.H. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004, 65:116-128.
7. Wada T., Furuichi K., Sakai N., Yoshimoto K., Shimizu M., Takeda S.I., et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000, 58:1492-1499.
8. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., Rollin B.J., Tesch G.H. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006, 69:73-80.
9. Sugimoto H., Shikata K., Hirata K., Akiyama K., Matsuda M., Kushiro M., et al. Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes 1997, 46:2075-2081.
10. Dipetrillo K., Coutermarsh B., Gesek F.A. Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 2003, 284:F113-21.
11. DiPetrillo K., Gesek F.A. Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol 2004, 24:352-359.
12. Mezzano S., Aros C., Droguett A., Burgos M.E., Ardiles L., Flores C., et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transpl 2004, 19:2505-2512.
13. You H., Lu Y., Gui D., Peng A., Chen J., Gu Y. Aqueous extract of Astragali Radix ameliorates proteinuria in adriamycin nephropathy rats through inhibition of oxidative stress and endothelial nitric oxide synthase. J Ethnopharmacol 2011, 134:176-182.
14. Zhang W.J., Hufnagl P., Binder B.R., Wojta J. Antiinflammatory activity of astragaloside IV is mediated by inhibition of NF-kappaB activation and adhesion molecule expression. Thromb Haemostasis 2003, 90:904-914.
15. Du Q., Chen Z., Zhou L.F., Zhang Q., Huang M., Yin K.S. Inhibitory effects of astragaloside IV on ovalbumin-induced chronic experimental asthma. Can J Physiol Pharmacol 2008, 86:449-457.
16. Li M., Qu Y.Z., Zhao Z.W., Wu S.X., Liu Y.Y., Wei X.Y., et al. Astragaloside IV protects against focal cerebral ischemia/reperfusion injury correlating to suppression of neutrophils adhesion-related molecules. Neurochem Int 2012, 60:458-465.
17. Chen J., Gui D., Chen Y., Mou L., Liu Y., Huang J. Astragaloside IV improves high glucose-induced podocyte adhesion dysfunction via α3β1 integrin upregulation and integrin-linked kinase inhibition. Biochem Pharmacol 2008, 76:796-804.
18. Gui D., Guo Y., Wang F., Liu W., Chen J., Chen Y., et al. Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo. PLoS ONE 2012, 7:e39824.
19. Yu J., Zhang Y., Sun S., Shen J., Qiu J., Yin X., et al. Inhibitory effects of astragaloside IV on diabetic peripheral neuropathy in rats. Can J Physiol Pharmacol 2006, 84:579-587.
20. Elmarakby A.A., Quigley J.E., Olearczyk J.J., Sridhar A., Cook A.K., Inscho E.W., et al. Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension. Hypertension 2007, 50:1069-1076.
21. -ΔΔCT method. Methods 2001, 25:402-408.
22. Schmid H., Boucherot A., Yasuda Y., Henge A., Brunner B., Eichinger F., et al. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 2006, 55:2993-3003.
23. Riad A., Du J., Stiehl S., Westermann D., Mohr Z., Sobirey M., et al. Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus. Eur J Pharmacol 2007, 569:204-211.
24. Jiang Q., Liu P., Wu X., Liu W., Shen X., Lan T., et al. Berberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: involvement of NF-κB signaling pathway. Mol Cell Endocrinol 2011, 331:34-40.
25. Guijarro C., Egido J. Transcription factor-kappa B (NF-kappaB) and renal disease. Kidney Int 2001, 59:415-424.
26. Park C.W., Kim J.H., Lee J.H., Kim Y.S., Ahn H.J., Shin Y.S., et al. High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappaB-dependent. Diabetologia 2000, 43:1544-1553.
27. Kuhad A., Sachdeva A.K., Chopra K. Attenuation of renoinflammatory cascade in experimental model of diabetic nephropathy by sesamol. J Agr Food Chem 2009, 57:6123-6128.
28. Soetikno V., Sari F.R., Veeraveedu P.T., Thandavarayan R.A., Harima M., Sukumaran V., et al. Curcumin ameliorates macrophage infiltration by inhibiting NF-κB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr Metab 2011, 8:35.
29. Okazaki T., Sakon S., Sasazuki T., Sakurai H., Doi T., Yagita H., et al. Phosphorylation of serine 276 is essential for p65 NF-kappaB subunit-dependent cellular responses. Biochem Biophys Res Commun 2003, 300:807-812.
30. Jain S.K., Velusamy T., Croad J.L., Rains J.L., Bull R. L-cysteine supplementation lowers blood glucose, glycated hemoglobin, CRP, MCP-1, and oxidative stress and inhibits NF-kappaB activation in the livers of Zucker diabetic rats. Free Radical Bio Med 2009, 46:1633-1638.
31. Zheng R., Deng Y., Chen Y., Fan J., Zhang M., Zhong Y., et al. Astragaloside IV attenuates complement membranous attack complex induced podocyte injury through the MAPK pathway. Phytother Res 2012, 26:892-898.
32. Zhang L., Liu Q., Lu L., Zhao X., Gao X., Wang Y. Astragaloside IV stimulates angiogenesis and increases hypoxia-inducible factor-1α accumulation via phosphatidylinositol 3-kinase/Akt pathway. J Pharmacol Exp Ther 2011, 338:485-491.
33. Navarro J., Milena F., Mora C., León C., Claverie F., Flores C., et al. Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin converting enzyme inhibition. Kidney Int Supp 2005, 99:S98-S102.
34. Navarro J.F., Mora C. Role of inflammation in diabetic complications. Nephrol Dial Transpl 2005, 20:2601-2604.
35. Nakamura T., Fukui M., Ebihara I., Osada S., Tomino Nagaoka.I., et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993, 42:450-456.
36. Sugimoto H., Shikata K., Wada J., Horiuchi S., Makino H. Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible oxide synthase in diabetic rat glomerli. Diabetologia 1999, 42:878-886.
37. Navarro J.F., Milena F.J., Mora C. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 2006, 26:562-570.
38. Banba N., Nakamura T., Matsumura M., Kuroda H., Hattori Y., Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 2000, 58:684-690.
39. Okada S., Shikata K., Matsuda M., Ogawa D., Usui H., Kido Y., et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003, 52:2586-2593.
40. Nerlich A., Schleicher E. Immunohistochemical localization of extracellular matrix components in human diabetic glomerular lesions. Am J Pathol 1991, 139:889-899.
41. Kato S., Luyckx V.A., Ots M., Lee K.W., Ziai F., Troy J.L., et al. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int 1999, 56:1037-1048.
42. Li C., Yang C.W., Park C.W., Ahn H.J., Kim W.Y., Yoon K.H., et al. Long-term treatment with ramipril attenuates renal osteopontin expression in diabetic rats. Kidney Int 2003, 63:454-463.